Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results

Author:

Wang Michael L.1,Blum Kristie A.2,Martin Peter3,Goy Andre4,Auer Rebecca5,Kahl Brad S.6,Jurczak Wojciech7,Advani Ranjana H.8,Romaguera Jorge E.1,Williams Michael E.9,Barrientos Jacqueline C.10,Chmielowska Ewa11,Radford John12,Stilgenbauer Stephan13,Dreyling Martin14,Jedrzejczak Wieslaw Wiktor15,Johnson Peter16,Spurgeon Stephen E.17,Zhang Liang1,Baher Linda18,Cheng Mei18,Lee Dana18,Beaupre Darrin M.18,Rule Simon19

Affiliation:

1. The University of Texas MD Anderson Cancer Center, Houston, TX;

2. Ohio State University Comprehensive Cancer Center, Columbus, OH;

3. Weill Cornell Medical College, New York, NY;

4. John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, NJ;

5. Barts Health National Health Service (NHS) Trust, London, United Kingdom;

6. University of Wisconsin School of Medicine and Public Health, Madison, WI;

7. Jagiellonian University, Krakow, Poland;

8. Stanford University Medical Center, Stanford, CA;

9. University of Virginia School of Medicine, Charlottesville, VA;

10. Hofstra North Shore-Long Island Jewish School of Medicine, Hempstead, NY;

11. Oddzial Kliniczny Onkologii, Centrum Onkologii, Bydgoszcz, Poland;

12. The University of Manchester and the Christie NHS Foundation Trust, Manchester, United Kingdom;

13. Universitatsklinikum Ulm, Klinik fur Innere Medizin II, Ulm, Germany;

14. University Hospital LMU Munich, Germany;

15. Medical University of Warsaw, Warsaw, Poland;

16. Cancer Research UK Clinical Centre, Southampton General Hospital, Southampton, United Kingdom;

17. Oregon Health and Science University, Portland, OR;

18. Pharmacyclics LLC, Sunnyvale, CA; and

19. Plymouth University Peninsula Schools of Medicine and Dentistry, Plymouth, United Kingdom

Abstract

Key Points Ibrutinib demonstrates durable responses and sustained single-agent activity in relapsed or refractory MCL at median 26.7-month follow-up. Ibrutinib shows a favorable benefit-risk profile over time, with a manageable safety profile.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3